In accordance to infectious etiology of the patient’s disease progression. Pateient was started with interavenous combination antibiotics Piperacillin-Tazobactam (4.5 gram four times a day) and Clarithromycin (500mg twice a day) and continued for 8 days. Antifungal therapy was initiated with oral itraconazole (200 mg three times daily). For symptomatic relief of allergic manifestations, oral bilastine (40 mg once daily) was administered. Bronchodilator therapy included oral combination of Etofylline and Theophylline combination (100 mg twice daily) along with nebulized Ipratropium bromide and l L Levosalbutamol combination (Duolin) administered at regular intervals. In addition, inhaled corticosteroid therapy with nebulized budesonide (Budecort) was given to reduce airway inflammation. Leukotriene receptor antagonist therapy with montelukast + levocetirizine combination (Montair LC) once daily was also prescribed. For fluid management and control of associated comorbidities, oral Torsemide + Spironolactone combination (Dytor Plus) was administered. Antihypertensive therapy included Diltiazem (thrice daily) to maintain hemodynamic stability. The patient showed gradual clinical improvement with the above management, with reduction in respiratory distress and stabilization of vital parameters. She was continued on the same regimen with close monitoring and supportive care. extend this in proper format of case report puclication b